Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)

Autor: Des Guetz, Gaetan, Landre, Thierry, Westeel, Virginie, Milleron, Bernard, Vaylet, Fabien, Urban, Thierry, Barlesi, Fabrice, Souquet, Pierre-Jean, Debieuvre, Didier, Braun, Denis, Fraboulet, Gislaine, Monnet, Isabelle, Uzzan, Bernard, Molinier, Olivier, Morin, Franck, Moro-Sibilot, Denis, Morère, Jean Francois
Zdroj: In Journal of Geriatric Oncology May 2015 6(3):233-240
Databáze: ScienceDirect
Externí odkaz: